Kenneth Bartizal
Keine laufenden Positionen mehr
Karriereverlauf von Kenneth Bartizal
Ehemalige bekannte Positionen von Kenneth Bartizal
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Corporate Officer/Principal | 04.06.2007 | - |
| MERCK & CO., INC. | Direktor/Vorstandsmitglied | 01.01.2007 | 01.04.2007 |
| Corporate Officer/Principal | 01.05.1987 | 01.04.2007 | |
| PFIZER, INC. | Corporate Officer/Principal | 01.01.1988 | 01.01.1988 |
| Kirksville College of Osteopathic Medicine, Inc. | Corporate Officer/Principal | 01.01.1983 | - |
| Truman State University | Corporate Officer/Principal | 01.01.1983 | - |
| CIDARA THERAPEUTICS, INC. | Corporate Officer/Principal | 01.07.2014 | - |
Ausbildung von Kenneth Bartizal
| University of Notre Dame | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 8 |
Operativ
| Corporate Officer/Principal | 6 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| CIDARA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
- Börse
- Insiders
- Kenneth Bartizal
- Erfahrung
